Proprietary pipeline of next generation immunology and immuno-oncology drugs.

numab graphic numab graphic numab graphic numab graphic

Highlights of tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first generation antibody therapies in terms of potency, stability, effect duration and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Latest News
May 02, 2019

CStone and Numab announce exclusive regional licensing agreement for ND021

Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals…

Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals (HKEX: 2616) and Numab Therapeutics AG today announce that they have entered into an exclusive regional licensing agreement for the development and commercialization of ND021, a potential best-in-class monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin (HSA).
April 01, 2019

Numab presents updates on ND021 program at AACR Annual Meeting 2019

Numab delivered a poster presentation today, providing new animal…

Numab delivered a poster presentation today, providing new animal data on its lead I/O drug candidate, NM21-1480, emerging from the company’s ND021 program. NM21-1480 is a PD-L1/4-1BB/HSA trispecific scMATCH3 that simultaneously blocks PD-(L)1 signaling and conditionally costimulates 4-1BB+ cells in the tumor microenvironment. The unique properties of NM21-1480 enables best-in-class antitumoral efficacy while avoiding extratumoral activity and thereby preventing any 4-1BB-mediated toxicities. Studies in mice and non-human primates support NM21-1480 as a safe and highly effective drug candidate for a variety of cancers. Please click here to view the poster.
March 05, 2019

Numab announces entry into a license agreement with Intarcia for anti-inflammatory ND016

Pfäffikon, Switzerland, March 5, 2019 – Numab Therapeutics AG…

Pfäffikon, Switzerland, March 5, 2019 – Numab Therapeutics AG today announced that Intarcia Therapeutics Inc. has executed its option to in-license ND016, being developed for the treatment of autoimmune disorders. Numab discovered ND016 on behalf of Intarcia under a previous research and option agreement. Under the present exclusive license agreement, Intarcia receives worldwide rights to develop and commercialize ND016 in exchange for license payments of up to CHF 70 million and up to double digit tiered royalties on net sales.
More News
Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept